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Outcomes of Catheter Ablation of PVC. Background: The purpose of this study was to assess how
well acute procedural outcomes predict the clinical outcome of catheter ablation of premature ventricular
complexes (PVCs).
Methods: A consecutive series of 50 patients (28 women, age: 51 ± 13 years) with frequent PVCs was
referred for PVC ablation. Acute failure was defined as inability to eliminate the predominant PVC or
recurrence of the predominant PVC within 12 hours. The PVC burden was reassessed 3 months after
the ablation procedure. A successful procedure was defined as reduction of the PVC burden at 3 months
by 80% of the initial burden.
Results: The procedure was acutely effective in 37 patients (74%) and at 3 months in 40 patients (80%).
The presence or absence of the predominant PVC in the 12 hours postablation had the highest accuracy
for outcome at 3 months (accuracy: 90%). From among the 13/50 patients (26%) with evidence of acute
failure, 4 had a PVC reduction of 80% at 3 months and 10 had a PVC reduction of >50% resulting in
symptomatic improvement at 3 months.
Conclusion: The presence or absence of the predominant PVC within 12 hours postablation best corre-
lated with the 3-month-efficacy data. Recurrence of the predominant PVC shortly after ablation did not
indicate a procedural failure and the necessity for a repeat procedure. The majority of these patients had
a significant, clinically meaningful reduction in their PVC burden. Acute predictors for procedural outcome
at 3 months have a high positive but rather low negative predictive value. (J Cardiovasc Electrophysiol, Vol.
25, pp. 597-601, June 2014)
premature ventricular complexes, catheter ablation, outcome
Background
Frequent premature ventricular complexes (PVCs) have been
targeted by radiofrequency ablation in patients with and with-
out structural heart disease.1-3 The factors that correlate with
PVC recurrence have not been systematically described. It is
unclear whether periprocedural elimination of a predominant
PVC is required for a successful outcome. The purpose of
this study was to assess determinants of 3-month efficacy in
patients who underwent ablation of frequent PVCs.
Methods
Patient Characteristics
In a consecutive series of 50 patients, (28 women, age:
51 ± 13 years, ejection fraction: 52 ± 12.6%; Table 1)
with frequent idiopathic PVCs who were referred for ab-
lation, telemetry was performed postablation for 12 hours.
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Patients with structural heart disease were excluded. Patients
failed 1 ± 1 antiarrhythmic medications including β-blocker
and calcium channel blocker therapy, and 31/50 patients
(62%) had undergone a prior failed attempted ablation proce-
dure. Forty-two patients had palpitations and the remaining
8 patients had an impaired left ventricular ejection fraction
(38.9 ± 9.4%), and 20 patients (40%) had pleomorphic PVCs
and the remainder had unimorphic PVCs.
Holter Recordings
A 24-hour 12-lead Holter was recorded before the abla-
tion procedure to determine the PVC burden. The recording
was repeated 3 months postablation. A predominant PVC
morphology was defined as a PVC accounting for >80% of
all PVC morphologies based on a 12-lead Holter recording.
A predominant PVC was present in 46/50 patients; in the re-
maining 4 patients the predominant PVC accounted for 75 ±
2% of all PVC morphologies. Immediately postprocedure,
the patients were connected to a 7-lead-telemetry unit that
was stored (General Electrics, CIC, Milwaukee, WI, USA)
and all patients were observed for at least 12 hours after ab-
lation. Each PVC was subsequently analyzed as to whether it
was the targeted PVC morphology or another PVC morphol-
ogy. The PVCs were quantified for 12 hours postprocedure
and the postprocedural PVC burden was compared to the
preprocedural PVC burden. Before ablation, variability of
the PVC burden was assessed with 2 different Holters 70 ±
121 days apart. The PVC burden of both Holters was similar
(P = 0.48).





Age (years) 51 ± 13
Male gender, n 22 (44)
Left ventricular ejection fraction (%) 54 ± 12
PVC burden (%) 19.7 ± 13
Therapy, n
β-Blockers 27 (54)
Calcium channel blockers 10 (20)
Antiarrhythmic drug therapy including amiodarone 9 (18)
Data are shown as mean ±1 standard deviation. Percentage values are shown
in parentheses. PVC = premature ventricular complex.
Electrophysiology Study
After informed consent was obtained, 3 quadripolar elec-
trode catheters were advanced via a femoral vein to the right
ventricular apex, the His position, and the high right atrium.
After vascular access was obtained, 3,000 units of heparin
was administered. If arterial access was also obtained, 5,000
units of heparin was given targeting an activated clotting
time of 250–300 seconds. Programmed ventricular stimula-
tion with up to 4 extrastimuli was performed to induce ven-
tricular tachycardia. Surface electrocardiographic leads were
recorded in combination with bipolar intracardiac tracings
and recorded on optical disc (EP Med Systems, West Berlin,
NJ, USA). Amount and the type of medication used dur-
ing the ablation procedure (midazolam, propofol, ketamine,
morphine, remifentanyl, or fentanyl) were recorded and com-
pared among the groups with failed and effective procedures.
Only conscious sedation and no general anesthesia was used
during the ablation procedures.
Mapping and Ablation
A 3-dimensional mapping system (CARTO, Biosense
Webster, Diamond Bar, CA, USA) was used for mapping
in all patients. Mapping was performed with 3.5-mm-open-
irrigated-tip catheter (Thermocool Navistar, Biosense Web-
ster). The site of origin was identified by activation mapping
in the presence of frequent PVCs; in the absence of frequent
PVCs, pace mapping was used to identify the site of origin.
A site of origin was defined as intramural when pacing at the
site of earliest activation from either side of the ventricular
cavity failed to show a matching pace map (<10/12 leads).4
Radiofrequency energy was delivered for 60–120 seconds at
the site of origin. An impedance drop of 10  was targeted
with a power of 30–50 W. If radiofrequency energy was
delivered in an aortic cusp or within the coronary venous
system, an initial power of 15–20 W was used. The ablation
endpoint was to eliminate the predominant PVCs. If other
PVCs were present, they were also targeted at the discretion
of the operator.
Definitions
The procedure was defined as acutely effective if the pre-
dominant PVC was eliminated and did not recur for 12 hours
postablation. Recurrence of the predominant PVC within 12
hours postablation was defined as acute failure of the ablation
procedure. At 3 months, a decrease by 80% of the initial
PVC burden was defined as an effective ablation procedure.
A partially effective procedure was defined arbitrarily as a
reduction in the PVC burden by 50–80% of the initial PVC
burden. The 12-lead morphology of the PVC-QRS complex
was compared to other PVC morphologies. PVCs were de-
fined as pleomorphic if they differed in at least 3/12 ECG
leads from another PVC morphology in a given patient.
Follow-Up
All patients had a Holter at 3 months postablation. They
were seen in follow-up 3–6 months postablation. Subse-
quently patients were seen on an as-needed basis. An-
tiarrhythmic drugs were discontinued postablation if the
procedure was successful. β-Blockers and calcium channel
blockers were continued only if there was an indication other
than the presence of PVCs. No new antiarrhythmic drugs
were added postablation.
Statistical Analysis
Continuous variables were expressed as mean ±1 standard
deviation and were compared with Student’s t-test. Categor-
ical variables were compared with the χ2 test. If the sample
size was smaller than 5 in a given cell, Fisher’s exact test
was used. A P value of <0.05 was considered statistically
significant. Paired sample t-tests were used to compare PVC
burden before and after ablation and for PVC variability.
Results
PVC Elimination and Outcome
Elimination of the predominant PVCs during the ablation
was achieved in 47/50 patients (94%). During the immediate
12-hour postprocedure, the predominant PVC did not recur
in 37/50 patients (74%). At 3 months, the predominant PVC
did recur in only 1/37 patients with an acutely effective proce-
dure. The PVC burden was reduced from 19 ± 13% to 1.1 ±
3.8% in the 12-hour postablation period and increased to
2.1 ± 4.5% at 3 months postablation (P values < 0.0001 for
each comparison with the initial PVC burden). Regardless of
the PVC burden within 12 hours postablation, the presence
or absence of the predominant PVC within 12 hours postab-
lation had the highest accuracy (90%) in predicting failure
or complete success of the procedure at 3 months (positive
predictive value: 97%, negative predictive value: 70%, sensi-
tivity: 90%, specificity: 90%). Reduction of the PVC burden
within 12 hours postprocedure (by 80% of the initial bur-
den) predicted the 3-month efficacy with an accuracy of 82%
(positive predictive value: 84%, negative predictive value:
60%, sensitivity: 95%, specificity: 30%).
In patients with an acutely successful procedure, the PVC
burden 3 months postablation was significantly lower com-
pared to patients with a failed acute procedure (1.1 ± 3.3%
vs. 5.1 ± 6.4%, P = 0.0001; Fig. 1).
At 3 months, 40/50 patients (80%) had a reduction
of 80% of the initial PVC burden and in a total of 46/50
patients (92%) the procedure reduced the initial PVC burden
by at least 50%.
With respect to procedural complications, 3 patients
had groin hematomas (no surgery required), 1 patient had
pericardial tamponade necessitating pericardiocentesis, and
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Figure 1. Preablation and 3 months postablation PVC burden in patients
with an acutely effective versus an acutely failed procedure. There was no
significant difference in the PVC burden preablation. The PVC burden at
3 months postablation was significantly reduced.
1 patient had a coronary venous dissection with minimal
pericardial effusion that was managed conservatively.
Failed Acute Ablation
The procedure acutely failed in 13/50 patients (26%). In
3/13 patients, the predominant PVCs could not be eliminated
during the ablation. A total 2 of these 3 patients had failed
procedures at 3 months. In 1/3 patients, PVCs disappeared
9 hours postablation and at the 3-month follow-up Holter
there was a 80% reduction compared to the initial PVC
burden. The PVC burden before the ablation in these 3 pa-
tients changed from 15 ± 11% preprocedure to 9 ± 12% at
3 months (ns).
On the other hand, in 10 patients (20%) the predomi-
nant PVC was eliminated during the ablation procedure and
did not recur within 1 hour postablation, yet PVCs returned
within 12 hours postprocedure. However, in 3/10 patients the
PVC burden was reduced by80% of the initial PVC burden
at 3 months and in 8/10 patients the PVC burden was reduced
by >50% of the initial PVC burden preablation at 3 months.
Thus in 10/13 patients (77%), the PVC burden at 3 months
was reduced by at least 50% and by80% of the initial bur-
den in 4 (29%) patients with acutely failed procedures. The
PVC burden in these 13 patients was reduced from 14.4 ±
11.0% to 5.1 ± 6.4% (P < 0.05).
The patients with effective or partially effective ablation
reported improvement of symptoms postablation.
There was no significant difference in whether or not se-
dation was administered during the ablation procedure or
which sedative was used (midazolam vs. propofol vs. fen-
tanyl) when patients with and without acute failure were
compared.
Pleomorphic PVCs and Predominant PVCs
Less than half of the patients (20 patients; 40%) had pleo-
morphic PVCs at the time of the ablation procedure. The
mean number of PVC morphologies per patient was 2.8 ±
3.3 (range: 1–15) and 1.34 ± 0.7 PVC morphologies were
mapped per patient (range: 1–4 per patient). A predominant
PVC, however, was present in the preprocedural Holter in
46/50 patients. The predominant PVC accounted for a mean
of 96% of the entire PVC burden (range: 73–100%). Despite
targeting the predominant PVC in all patients, in patients
with pleomorphic PVCs the success rate was lower (65% vs.
90%, P = 0.036) at 3 months. There was, however, no differ-
ence when patients with and without pleomorphic PVCs were
compared with respect to acute outcome (65% vs. 80%, P =
0.33). A nonpredominant PVC became the predominant PVC
in 1/20 patients with pleomorphic PVCs during follow-up.
PVC Origin and Outcome
The site of origin of the predominant PVC (Fig. 2,
Table 2) was from the right ventricular outflow tract (n =
11), an intramural focus (n = 9), the epicardium (n = 7),
the papillary muscles (n = 6), the pulmonary artery (n =
7), the aortic cusps (n = 2), the left ventricular outflow tract
(n = 3), the fascicles (n = 2), the mitral annulus (n = 1),
the aorto-mitral continuity (n = 1), and the tricuspid annulus
Figure 2. Site of origin of predomi-
nant PVCs. The numbers in parenthe-
ses indicate number of patients with suc-
cess/failure at 3 months postablation.
For a high quality, full color version of
this figure, please see Journal of Car-
diovascular Electrophysiology’s website:
www.wileyonlinelibrary.com/journal/jce
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TABLE 2
Acute and 3-Month Success Rates with Respect to the Site of Origin of
PVCs
Acutely
Effective Acute 3 Month 3 Month
PVC Site of Origin, n Procedure Failure Success Failure
Cusp, 2 2 (100) 0 2 (100) 0
Pulmonary artery, 7 6 (86) 1 (14) 7 (100) 0
RVOT, 11 9 (82) 2 (18) 9 (82) 2 (18)
Papillary muscle, 6 3 (50) 3 (50) 4 (67) 2 (33)
Epicardial, 7 6 (86) 1 (14) 6 (86) 1 (14)
Intramural, 9 7 (78) 2 (22) 7 (78) 2 (22)
LVOT, 3 2 (67) 1 (33) 2 (67) 1 (33)
Fascicular, 2 0 2 (100) 1 (50) 1 (50)
Mitral annulus, 1 0 1(100) 0 1 (100)
Tricuspid annulus, 1 1 (100) 0 1 (100) 0
Aorto-mitral continuity, 1 1 (100) 0 1 (100) 0
Total, 50 37 (74) 13 (26) 40 (80) 10 (20)
Percentage values are shown in parentheses. The indicated numbers of suc-
cess and failure at 3 months do not include the numbers of acute results.
LVOT = left ventricular outflow tract; PVC = premature ventricular com-
plex; RVOT = right ventricular outflow tract.
(n = 1). In 2 patients the site of origin of the predominant
PVC was the aortic cusps, in 3 the left ventricular outflow
tract, fascicular in 2 patients, the mitral annulus in 1 patient,
aortomitral continuity in 1 patient, and tricuspid annulus in
1 patient. In 5 patients, there was a late improvement in the
PVC burden at 3 months follow up. The site of origin of the
PVCs in these patients were: the papillary muscles (n = 2),
the pulmonary artery (n = 1), the epicardium (n = 1), and the
fascicular system (n = 1). No site of origin was predictive of
the outcome at 3 months postablation (P = 0.27).
Discussion
In this study of patients with frequent PVCs, targeting
the predominant PVC morphology resulted in a substantial
reduction of the PVC burden in almost 90% of patients. The
strongest predictor of 3-month efficacy was the absence of
the predominant PVC during the 12-hour period postabla-
tion. However, persistence or recurrence of the predominant
PVC early postablation did not predict procedural failure at
3 months.
Predictors of Outcome: Acute Effective Ablation
Elimination of the targeted PVC for 12 hours postproce-
dure was the best predictor for a favorable 3-month outcome.
In the patients with acute success, the site of origin of the
PVC was reached and eliminated. Recurrence was rare if the
PVCs did not recur within the periprocedural observation
period and was documented in only 1 patient with acute pro-
cedural success. It is unlikely that day-to-day variations of
the PVC burden accounted for the decrease in the PVC bur-
den acutely and at 3 months postablation since the variation
of the PVC burden before the ablation was not significant
based on 2 preprocedural Holters. Furthermore, the stability
of the PVC burden in patients without ablation has been re-
ported over a much longer time period than in this study.5
Also, type and amount of sedation given during the ablation
procedure did not differ between patients, and sedation is
therefore unlikely to have resulted in the acute change of the
PVC burden postprocedure.
Predictors of Outcome: Acute Failed Ablation
Complete elimination of the predominant PVC for 12
hours postablation or for even 1 hour postablation may not
be possible in every patient; and patients with frequent PVCs
may still benefit from an ablation and have symptomatic
improvement, even if the PVC burden is only reduced by
50% rather than 80% of the initial burden. In about 70%
of the patients in whom acute outcome measures suggested
a procedural failure, the PVC burden was substantially re-
duced at the 3-month follow-up. It appears that patients
in whom elimination of the PVCs during the procedure
was achieved despite their recurrence within 12 hours had
a better outcome than the patients in whom this was not
possible.
Procedural failure can be divided into the inability to com-
pletely eliminate the predominant PVC during the ablation
procedure and recurrence of the predominant PVC within 12
hours postprocedure. In the former group of patients, the site
of origin was not reached or originated close to the conduc-
tion system. In these patients, elimination of PVCs was not
seen acutely and patients still had a high PVC burden at the
3-month follow-up Holter.
In the latter form where PVCs recurred after elimination
of the PVCs during the ablation procedure, edema forma-
tion during radiofrequency energy delivery might have ac-
counted for the disappearance of the targeted PVC acutely
and its recurrence later in the early postablation period. The
arrhythmogenic substrate was altered, since the 3-month
follow-up showed a significant reduction of the preproce-
dural PVC burden in the patients with early recurrence of
PVCs. Lesion maturation may be a factor that accounts for
this observation.6
Predominant PVC and Other PVCs
For ventricular tachycardia (VT), complete elimination is
used as a definition for acute success and a single recurrence
is defined as failure. For PVCs, a less stringent definition
of reduction of the PVC burden by at least 80% of the ini-
tial burden is often used accounting for pleomorphic PVCs
and the fact that most often a predominant PVC is targeted
only. In the majority of the patients in this series there was
indeed a predominant PVC, and the strategy to eliminate
the predominant PVC was effective in most patients and re-
sulted in clinical benefit in almost 90% of patients. However,
pleomorphic PVCs remain a problem and, not unexpectedly,
the success rate in these patients is lower. It remains to be
determined whether targeting nonpredominant PVCs will in-
crease the success rate at 3 months. Dynamic changes in the
immediate postprocedural period may account for the rise
in the PVC burden from 12 hours postablation to 3 months
postablation. And therefore it is not surprising that the re-
duction of the PVC burden at 12 hours postablation was the
least accurate predictor of the 3-month outcome.
Assessment of the procedural success may not be possi-
ble right after the procedure and may take up to 3 months
especially if the predominant PVC recurs postablation. Since
patients had clinical benefit even if the PVC burden was not
reduced by 80% of the initial value, we propose to also
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use a definition of partial success where the PVC burden has
been reduced to a lower level.
Limitations
A 7-lead recording system was used for postprocedure
telemetry. It is therefore possible that the PVC morphologies
might not have been accurately classified as the predominant
or nonpredominant PVC, especially in patients with pleo-
morphic PVCs. However, a PVC was only defined as the
predominant PVC on telemetery if it had the same bundle
branch block morphology, the same axis and other similar
morphology characteristics compared to the 12-lead ECG
morphology of the predominant PVC. Since repeat Holters
were not performed for all patients postablation, it is possible
that a normal variation might have accounted for a reduced
PVC burden in some individual patients. This is a small series
of patients including patients with previously failed ablations
and patients with PVCs originating from papillary muscles as
well as the epicardium. A longer follow-up period is required
especially in patients with pleomorphic PVCs to determine
the value of targeting only the predominant PVC.
Conclusions
Elimination of the predominant PVC for a period of 12
hours postprocedure best predicts the 3-month outcome for
PVC ablation. Recurrence of the predominant PVC shortly
after ablation does not indicate a procedural failure and the
necessity for a repeat procedure. Yet the majority of these pa-
tients still had a significant, clinically meaningful reduction
in their PVC burden. Acute outcomes measures are imperfect
in predicting 3-month outcomes post-PVC ablation.
References
1. Bogun F, Crawford T, Reich S, Koelling TM, Armstrong W, Good E,
Jongnarangsin K, Marine JE, Chugh A, Pelosi F, Oral H, Morady F:
Radiofrequency ablation of frequent, idiopathic premature ventricular
complexes: Comparison with a control group without intervention. Heart
Rhythm 2007;4:863-867.
2. Sarrazin JF, Good E, Kuhne M, Oral H, Pelosi F Jr, Chugh A, Jong-
narangsin K, Crawford T, Ebinger M, Morady F, Bogun F: Mapping and
ablation of frequent post-infarction premature ventricular complexes. J
Cardiovasc Electrophysiol 2010;21:1002-1008.
3. Mountantonakis SE, Frankel DS, Gerstenfeld EP, Dixit S, Lin D,
Hutchinson MD, Riley M, Bala R, Cooper J, Callans D, Garcia F, Zado
ES, Marchlinski FE: Reversal of outflow tract ventricular premature
depolarization-induced cardiomyopathy with ablation: Effect of resid-
ual arrhythmia burden and preexisting cardiomyopathy on outcome.
Heart Rhythm 2011;8:1608-1614.
4. Yokokawa M, Good E, Crawford T, Chugh A, Pelosi F Jr, Latchamsetty
R, Jongnarangsin K, Ghanbari H, Oral H, Morady F, Bogun F: Rea-
sons for failed ablation for idiopathic right ventricular outflow tract-like
ventricular arrhythmias. Heart Rhythm 2013;10:1101-1108.
5. Niwano S, Sasaki T, Kurokawa S, Kiryu M, Fukaya H, Hatakeyama Y,
Niwano H, Fujiki A, Izumi T: Predicting the efficacy of antiarrhyth-
mic agents for interrupting persistent atrial fibrillation according to
spectral analysis of the fibrillation waves on the surface ECG. Circ J
2009;73:1210-1218.
6. Langberg JJ, Borganelli SM, Kalbfleisch SJ, Strickberger SA, Calkins
H, Morady F: Delayed effects of radiofrequency energy on acces-
sory atrioventricular connections. Pacing Clin Electrophysiol 1993;16
(Pt 1):1001-1005.
